UK Approves Incyte's Retifanlimab for Advanced Merkel Cell Skin Cancer
INCY sits 75% above its 52-week low of $66.85.
Summary
Incyte's Retifanlimab (Zynyz) has received approval from the UK's MHRA for advanced Merkel Cell Skin Cancer. This expands the drug's market access into a major European country, adding a new revenue stream for the company's oncology division. The approval provides a new treatment option for a rare but aggressive cancer. This positive regulatory news continues a strong run for Incyte, following recent FDA approvals and significant pipeline acquisitions.
At the time of this announcement, INCY was trading at $117.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.3B. The 52-week trading range was $66.85 to $118.69. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.